1. Antivirals
1.1. Viruses (In General)
1.1.1. Viral DNA Polymerase Inhibitors
1.1.1.1. Nucleoside Analogue - Prodrugs
1.1.1.1.1. Aciclovir (G analogue)
1.1.1.1.2. Valaciclovir
1.1.1.1.3. Ganiciclovir (G analogue)
1.1.1.1.4. Famiciclovir (Prodrug of Penciclovir)
1.1.1.1.5. Penciclovir
1.1.1.2. Non-Nucleoside Analogue
1.1.1.2.1. Foscarnet
1.1.1.2.2. Cidofovir
1.2. HIV
1.2.1. Older Drugs
1.2.1.1. Viral RNA Reverse Transcriptase Inhibitor
1.2.1.1.1. Nucleoside RT Inhibitor (NRTI) - Prodrugs
1.2.1.1.2. NucleoTide RT Inhibitor (NtRTI)
1.2.1.1.3. Non-Nucleoside RT Inhibitors (NNRTI)
1.2.1.2. Viral RNA Protease Inhibitors
1.2.1.2.1. Saquinavir
1.2.1.2.2. Ritonavir
1.2.1.2.3. Indinavir
1.2.2. Newer Drugs
1.2.2.1. Fusion Inhibitor
1.2.2.1.1. Enfurvititide
1.2.2.2. Co-Receptor Inhibitor
1.2.2.2.1. Maraviroc
1.2.2.3. Integrase Inhibitor
1.2.2.3.1. Raltegravir
1.3. Hepatitis Virus
1.3.1. Hepatitis B
1.3.1.1. Interferons +
1.3.1.1.1. Reverse Transcriptase Inhibitors (Many originally developed for HIV)
1.3.2. Hepatitis C
1.3.2.1. Protease Inhibitors ("-previr" suffix)
1.3.2.1.1. Biceprevir
1.3.2.1.2. Telaprevir
1.3.2.1.3. Simeprevir
1.3.2.2. Polymerase Inhibitors
1.3.2.2.1. Sofosbuvir
1.4. Influenza Virus
1.4.1. M2 Inhibitors (A type only)
1.4.1.1. Amantadine (Symmetrel)
1.4.1.2. Rimatadine (Flumadine)
1.4.2. Neuraminidase inhibitors (A and B type)
1.4.2.1. Zanamivir (Relenza)
1.4.2.1.1. Inhalation administration
1.4.2.2. Oseltamavir (Tamiflu)
1.4.2.2.1. Oral administration
2. Antibiotics
2.1. Inhibition of Cell Wall Synthesis
2.1.1. Beta-Lactams
2.1.1.1. Penicillin
2.1.1.1.1. Narrow Spectrum, Beta Lactamase Sensitive
2.1.1.1.2. Broad Spectrum, Beta-Lactamase Sensitive
2.1.1.1.3. Extended Spectrum, Beta Lactamase Sensitive
2.1.1.1.4. Penicillinase (Beta-lactamase)-Resistant
2.1.1.2. Cephahlosporins
2.1.1.3. Monobactams
2.1.1.4. Carbapenems
2.1.2. Vancomysin - on reserve
2.1.3. Bacitraicin
2.1.4. Cycloserine
2.2. Injury to Plasma Membranes
2.2.1. Polymixin
2.3. Interfere with Protein Synthesis
2.3.1. Lincosamides
2.3.2. Binds to 30S Ribosomal Subunit
2.3.2.1. Competition with tRNA for "A" Site
2.3.2.1.1. Tetracycline
2.3.2.2. Abnormal condon-anticondon binding -> misreading
2.3.2.2.1. Aminoglycosides
2.3.3. Binds to 50S Ribosomal Subunit
2.3.3.1. Inhibition of Transpeptidation
2.3.3.1.1. Chloramphenicol
2.3.3.2. Inhibition of Translocation
2.3.3.2.1. Macrolides
2.3.3.3. Premature Termination
2.3.3.3.1. Puromycin
2.3.3.4. Oxazolidinones - Linezolid
2.4. Interfere with Folate Synthesis or Action
2.4.1. Sulphonamides - Inhibits Dihydropteroate Synthetase
2.4.2. Trimethoprim - Inhibits Dihydrofolate Reductase
2.5. Interfere with DNA Synthesis
2.5.1. Fluroquinolones - Targets Topoisomerase II
2.5.1.1. Narrow Spectrum
2.5.1.1.1. Nalidixic Acid (not fluorinated}
2.5.1.2. Broad Spectrum (newer)
2.5.1.2.1. Ciproflaxcin
2.5.1.2.2. Levofloxacin
2.5.1.2.3. Gemifloxacin
2.5.2. Metronidazole - Binds and Destabilize Bacterial DNA
2.5.2.1. Antiprotozoal
2.5.2.2. Antibacterial
2.6. Interfere with RNA Synthesis
2.6.1. Rifampicin
3. Antifungals
3.1. Polyenes
3.1.1. Amphotericin B
3.1.2. Nystatin
3.2. Azole Agents
3.2.1. Imadazoles
3.2.1.1. Ketoconazole
3.2.2. Triazoles
3.2.2.1. Fluconazole
3.2.3. Broad Spectrum Triazoles
3.3. Allyamine
3.3.1. Terbinafine (Interferes with ergosterol biosynthesis)
3.4. Flucytocine
3.4.1. Antimetabolite pro-drug that inhibits thymidylate synthase
3.5. Griseofulvin
3.5.1. Binds to microtubles and affects mitosis
3.6. Echinocandins
3.6.1. Affects B-(1,3) Glucan Synthase